The addition of niacin to existing medical regimens for patients with heart disease and well-controlled LDL levels improves inflammatory markers, according to researchers at Tufts-New England Medical Center in Boston, Massachusetts.
In their study, niacin was added to existing therapy for three months in 54 participants with stable coronary artery disease. Average total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels were similar between groups.
“Three months of niacin treatment increased total HDL [good] by 7.5 percent and decreased triglycerides by 15 percent.”
In addition, taking niacin decreased lipoprotein-associated phospholipase A2 and C-reactive protein levels, both inflammation markers that have been implicated in heart disease.
The American Journal of Cardiology, September 15, 2006